Zareifar Soheila, Haghpanah Sezaneh, Shorafa Eslam, Shakibazad Nader, Karamizadeh Zohreh
Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Department of Pediatrics, Shiraz University of Medical Sciences, Shiraz, Iran.
Indian J Med Paediatr Oncol. 2017 Apr-Jun;38(2):97-102. doi: 10.4103/ijmpo.ijmpo_69_16.
Obesity is among the medical problems in survivors of childhood acute lymphoblastic leukemia (ALL). These patients are at risk of metabolic syndrome (MS). The present study aimed to follow the patients with ALL regarding the incidence of MS.
This study was conducted on all patients who referred to the oncology clinic from July 2012 to July 2013. The exclusion criteria of the study were ALL relapse, secondary malignancy, hypothyroidism, Down syndrome, and below 2 years of age. ALL had to be diagnosed at least 12 months before enrollment into this study. MS was assessed by serum triglyceride, cholesterol, fasting blood sugar, leptin, and insulin levels. Besides, body mass index (BMI) and blood pressure (BP) were measured at diagnosis and at the last visit.
This study was conducted on 53 patients (male = 35, female = 18). At the end of the study, 13 patients (24.53%) were overweight compared to 3 patients at diagnosis ( = 0.04). The mean blood leptin level was higher in overweight patients compared to the others ( = 0.001). MS was detected in 21 patients (39.6%), including 12 males and 9 females. In addition, the BMI -score significantly increased over the study period ( = 0.001).
Being overweight is a complication of ALL treatment, which is associated with elevated blood leptin level and BMI -score. Therefore, MS criteria, such as BP, weight, and serum triglyceride level, should be taken into account in each visit.
肥胖是儿童急性淋巴细胞白血病(ALL)幸存者面临的医学问题之一。这些患者有患代谢综合征(MS)的风险。本研究旨在追踪ALL患者的MS发病率。
本研究对2012年7月至2013年7月转诊至肿瘤门诊的所有患者进行。研究的排除标准为ALL复发、继发性恶性肿瘤、甲状腺功能减退、唐氏综合征以及年龄低于2岁。ALL必须在入组本研究前至少12个月被诊断。通过血清甘油三酯、胆固醇、空腹血糖、瘦素和胰岛素水平评估MS。此外,在诊断时和末次随访时测量体重指数(BMI)和血压(BP)。
本研究纳入53例患者(男性 = 35例,女性 = 18例)。研究结束时,13例患者(24.53%)超重,而诊断时为3例(P = 0.04)。超重患者的平均血瘦素水平高于其他患者(P = 0.001)。21例患者(39.6%)检测出MS,包括12例男性和9例女性。此外,研究期间BMI评分显著增加(P = 0.001)。
超重是ALL治疗的一种并发症,与血瘦素水平升高和BMI评分相关。因此,每次就诊时都应考虑MS标准,如血压、体重和血清甘油三酯水平。